A year-and-a-half ago, Howard Brody of the University of Texas Medical Branch in Galveston wrote an opinion article in the New England Journal of Medicine calling on every medical specialty to develop ways of cutting the cost of care. Citing financial sacrifices that had been made by insurers, hospitals, drug and device companies in the then pending health care reform bill, Brody said physicians could do their part “if they were willing to practice more in accordance with evidence-based guidelines and to study more seriously the data on regional practice variations.”
Toward that end, he called on each specialty to come up with a list that “would consist of five diagnostic tests or treatments that are very commonly ordered by members of that specialty, that are among the most expensive services provided, and that have been shown by the currently available evidence not to provide any meaningful benefit to at least some major categories of patients for whom they are commonly ordered.”
In the NEJM last week, two oncology specialists — Thomas Smith and Bruce Hilner of Virginia Commonwealth University — took up the challenge. They created a “top five” list of common oncology practices, which, if limited to situations where they were truly clinically useful, would sharply lower the cost of cancer care. Their lead paragraph noted the need for taking these steps:
Annual direct costs for cancer care are projected to rise — from $104 billion in 2006 to over $173 billion in 2020 and beyond. This increase has been driven by a dramatic rise in both the cost of therapy and the extent of care. In the United States, the sales of anticancer drugs are now second only to those of drugs for heart disease, and 70% of these sales come from products introduced in the past 10 years. Most new molecules are priced at $5,000 per month or more, and in many cases the cost-effectiveness ratios far exceed commonly accepted thresholds. This trend is not sustainable.
Look closely at the second to last sentence of that paragraph: “In many cases the cost-effectiveness ratios far exceed commonly accepted thresholds.” It’s worth noting that there are no commonly accepted thresholds for cost of care in the U.S. That’s not true in Great Britain, where the National Health Service, based on recommendations from the National Institute for Clinical Excellence, will refuse to pay for certain drugs when their costs exceed certain levels. But in the U.S., Medicare, which is the primary payer for most cancer care since cancer is primarily a disease of aging, is forbidden by law from taking cost into consideration. If the Food and Drug Administration has approved a specific approach, and the doctor prescribes it, Medicare will pay for it. If the oncologist tries an approach that is not specifically approved by the FDA — either as an “off label” use or combination of approved drugs — the Centers for Medicare and Medicaid Services will still pay for the treatments long as the approach is listed in clinical practice guidelines. And when it comes to most testing and imaging, most insurers including Medicare will pay for whatever the doctor orders, even though the medical literature is loaded with studies suggesting their lack of usefulness in many situations where commonly used.
That’s why oncologists themselves have to take this issue on. Here’s their top five list of new rules for controlling the cost of cancer care:
- Only use testing and imaging where “benefit has been shown”;
- Limit second-line and third-line treatments to metastatic cancer to sequential monotherapies for most solid tumors. “Patients will live just as long but will avoid toxic effects. . . Society will benefit from cost reductions associated with less chemotherapy, fewer supportive drugs, and fewer toxicity-associated hospitalizations”‘;
- Don’t give chemotherapy to people when their cancer has made them so weak that a positive response is highly unlikely;
- Lower chemo doses to eliminate the routine use of drugs that replace the white blood cells destroyed by toxic chemo drugs; and
- Stop treating patients if they haven’t responded to three different drug regimens — unless they are enrolled in a clinical trial actually testing the fourth regimen.
They also came up with a list of five changes in physician and patient attitudes that must take place to cut the cost of care, ranging from support for end-of-life counseling to more support for hospice and palliative care. “We understand that this will be extraordinarily difficult, since one person’s cost constraint is another person’s perceived lifesaving benefit and yet another’s income,” the two authors write. However, “there really is no other way. Our intention is to encourage other specialties to do the same and flatten the cost curve so that patients can continue to get the best new therapies.”
Now, here’s my top five list of how the editorial page of the Wall Street Journal will respond to this call for rationing based on science and common sense:
- It’s rationing that abrogates physician autonomy;
- It’s rationing that prevents individual choice in evaluating the trade-offs between benefits and risks;
- It’s rationing that denies very ill patients hope;
- It’s rationing that puts cost ahead of best practices; and
- Did I mention that it’s rationing?
And as far as end-of-life counseling is concerned, we’ve already heard right-wing politicians crying “death panels.”
I congratulate Smith and Hilner for taking on the Brody challenge. But there was one other issue I wish they had addressed. Why are cancer drugs of marginal efficacy so expensive? Why does a drug that extends life by a month or two cost $5,000 to $10,000 a month for the last year or two of a person’s life, thus adding up to a quarter million dollars to the cost of end-of-life care?
One could write a book about why there’s no economic justification for these sky-high prices (See this one, for instance). Last year, two Sloan Kettering researchers, writing in Health Affairs, proposed pricing new cancer drugs at the medical value they deliver — so-called reference pricing. I wrote about it here.
There’s a lot that oncologists can do to reduce the cost of care through eliminating unnecessary tests, images and treatments. But they should also begin raising their voices when they see drug companies charging an arm and a leg for products that they know, better than anyone else, really aren’t worth the money.
Merrill Goozner has been writing about economics and health care for many years. The former chief economics correspondent for the Chicago Tribune, Merrill has written for a long list of publications including the New York Times, The American Prospect, The Washington Post and Financial Times. You can read more pieces by him at GoozNews, where this post first appeared.